Document:

Amendment #1 to Amended and Restated Employment Agreement / Stefan Aigner

 Exhibit 10.11(a) 
  
 AMENDMENT NO. 1 TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT 
  
 This Amendment No. 1 to Amended and Restated Employment Agreement (this
“Amendment”) dated as of October 1, 2003 is entered into between Reliant Pharmaceuticals, LLC (the “Employer”) and Stefan Aigner (the “Employee”). 
  
 WITNESSETH: 
  
 WHEREAS, the Employer and the Employee are party to the Amended and Restated
Employment Agreement dated as of July 6, 2000 (the “Original Agreement”); 
  
 WHEREAS, the Employer and the Employee wish to amend the Original Agreement in the manner set forth herein to clarify such agreement. 
  
 NOW THEREFORE, in exchange for the agreements set forth herein, and good and valuable consideration the receipt and
sufficiency of which are hereby acknowledged, the Employer and the Employee hereby agree as follows: 
  
 1. Amendment of Section 5. Section 5 of the Original Agreement is hereby amended by adding the following new subsection (c) thereto: 
  
 “(c) The foregoing notwithstanding, 
  
 (i) in the event that Employer provides notice of
non-renewal at least 9 months prior to the then effective expiration date of this Agreement, Employer shall pay to Employee an amount equal to 25% of Employee’s Base Salary in effect as of the date of such notice of non-renewal; 
  
 (ii) in the event that Employer provides notice of
non-renewal at least 6 months (but less than 9 months) prior to the then effective expiration date of this Agreement, Employer shall pay to Employee an amount equal to 50% of Employee’s Base Salary in effect as of the date of such notice of
non-renewal; 
  
 (iii) in the event that Employer
provides notice of non-renewal at least 3 months (but less than 6 months) prior to the then effective expiration date of this Agreement, Employer shall pay to Employee an amount equal to 75% of Employee’s Base Salary in effect as of the date of
such notice of non-renewal; 
  
 (iv) in the event
that Employer provides notice of non-renewal less than 3 months prior to the then effective expiration date of this Agreement, Employer shall pay to Employee an amount equal to 100% of Employee’s Base Salary in effect as of the date of such
notice of non-renewal 
  
 (v) Employee will not
be entitled to any Bonus Compensation, Additional Bonus Compensation or benefit continuation (except as required by applicable law) in the event that this Agreement expires as the result of non-renewal by Employer or Employee; 
  
 (vi) all payments made to Employee pursuant to this Section
5(c) shall be made in accordance with Employer’s regular payroll practices (and not in a lump sum), including, without limitation, timing of payments and withholding; 

 (vii) if during the period that Employee is to receive payments from Employer under this
Section 5(c), Employee earns and/or receives compensation for services rendered from any person or entity, whether as an employee or otherwise, such compensation shall reduce the payments due under this Section 5(c) dollar for dollar. Employee
agrees that he will report any such compensation to Employer promptly upon earning and/or receiving same; and 
  
 (viii) Employer’s obligation to make payments under this Section 5(c) is expressly conditioned on receipt from Employee of an
executed General Release of Claims substantially in the form attached hereto as Exhibit D.” 
  
 2. Exhibit D. Annex 1 attached hereto shall be attached to the Original Agreement (as amended hereby) as Exhibit D thereto. 
  
 3. No Other Amendments. Except as expressly amended hereby the
Original Agreement shall continue in full force and effect. 
  
 4.
Governing Law. This Amendment shall be governed by, and construed in accordance with, the laws of New Jersey without giving effect to the choice of law provisions thereof. 
  
 5. Counterparts. For the convenience of the parties hereto, this Amendment may be executed in any number of
counterparts, each such counterpart being deemed to be an original instrument, and all such counterparts shall together constitute the same agreement. 
  
 6. Successors and Assigns. This Amendment shall be binding upon and inure to the benefit of the parties hereto and each of their successors and
assigns, including, without limitation, any successors or surviving entities thereto by operation of merger or conversion from a limited liability Employer to a corporation. 
  
 7. Entire Agreement. The Original Agreement, as amended hereby, constitutes the entire agreement of all parties
hereto with respect to the subject matter hereof and supersedes all prior agreements and undertakings, both written and oral, among the parties hereto with respect to the subject matter hereof. All references in the Original Agreement to “this
Agreement”, “hereof”, “hereby” and words of similar import shall refer to the Original Agreement as amended hereby. 
  
 8. Defined Terms. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the Original Agreement.

  
 [Signature Page Follows] 

 IN WITNESS WHEREOF, and intending to be legally bound, the Employer and the Employee have executed this
Amendment No. 1 to Amended and Restated Employment Agreement as of the date first written above. 
  

			
	EMPLOYEE:
	
	 /s/ Stefan Aigner

	Stefan Aigner
	
	EMPLOYER:
	
	RELIANT PHARMACEUTICALS, LLC
		
	By:	 	 /s/ Ernest Mario

	Name:	 	Ernest Mario
	Title:	 	CEO

 ANNEX 1 
 to 
 AMENDMENT NO. 1 TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT 
  
 (see attached) 

 EXHIBIT D 
  

GENERAL RELEASE OF CLAIMS 
  
 WHEREAS, Stefan Aigner (“Employee”) is/was employed by Reliant Pharmaceuticals, LLC (and any successor entity
“Employer”); 
  
 WHEREAS, Employee and Employer
are party to the Amended and Restated Employment Agreement (as amended from time to time, the “Employment Agreement”); and 
  
 WHEREAS, as a condition to Employee’s receipt of any payments under Section 5(c) of the Employment Agreement, Employee has agreed to execute and
deliver this General Release of Claims on behalf of himself and the Employer Related Parties (as defined below). 
  
 1. Except for (i) claims for indemnification under the Employer’s Operating Agreement (or other charter documents) or (ii) applicable directors and
officers liability insurance (if any) in respect of third-party claims, Employee unconditionally and forever remises, releases, discharges and holds harmless, and agrees to indemnify, the Employer and each and every owner, director, officer,
manager, employee, agent, representative, parent, subsidiary, affiliate, and related business entity of the Employer (collectively, the “Employer Releasees”) of and from any and all actions, causes of action, suits, debts, accounts,
liabilities, covenants, contracts, disputes, agreements, promises, claims and demands, of any kind or nature whatsoever, fixed or contingent, whether at law or in equity, which Employee had, now has or may have against any or all of the Employer
Releasees, whether or not currently known, arising from or relating to Employee’s employment and/or termination of employment with the Employer or any other event, dispute or occurrence which arose on or prior to the date hereof (collectively,
the “Employer Released Claims”), including, but not limited to, any and all claims: 
  
 a. arising from Employee’s employment, compensation, commissions, deferred compensation plans, insurance, equity options, restricted units, employee
benefits, and other terms and conditions of employment or employment practices of the Employer under federal, state or local law or regulation, including, but not limited to the Employee Retirement Income Security Act of 1974, as amended, and COBRA;

  
 b. relating to the termination of Employee’s employment
or the surrounding circumstances thereof; 

 c. based on any alleged discrimination on the basis of race, color, religion, sex, age, national origin,
handicap, disability or another category protected by any federal, state or local law or regulation, including, but not limited to, the Age Discrimination in Employment Act of 1967, as amended (29 U.S.C. §§ 621 et seq.),
Title VII of the Civil Rights Act of 1964 (42 U.S.C. §§ 2000e et seq.), The Civil Rights Act of 1991, Sections 1981 through 1988 of Title 42 of the United States Code (42 U.S.C. §§ 1981-88), the Americans with
Disabilities Act (42 U.S.C. §§ 12101 et seq.), the Family and Medical Leave Act of 1993, the Fair Labor Standards Act (29 U.S.C. §§ 201 et seq.), the Older Workers Benefit Protection Act of 1990, or
Executive Order 11246 (as any of these laws or orders may have been amended) or any other similar federal, state or local labor, employment or anti-discrimination laws; 
  
 d. based on any contract, tort, whistleblower, personal injury, or retaliatory or wrongful discharge theory; and

  
 e. based on any other federal, state or local constitution,
regulation, law (whether statutory or common), or legal theory. 
  
 2. Employee specifically waives the benefits of any statutory or common law of any state, which in effect provides that a general release does not extend to claims which the creditor does not know or suspect to exist in his favor. It is
expressly understood and agreed that the releases contained in this General Release of Claims are intended to cover and do cover all known facts and/or claims, as well as any further facts and/or claims within the scope of such released claims not
known or anticipated, but which may later develop or be discovered, including all the effects and consequences thereof. Employee acknowledges that he may hereafter discover facts in addition to, or different from, those which he now believes to be
true with respect to the subject matter of the claims released herein, but agrees that he has taken that possibility into account in reaching this General Release of Claims, and that the releases given herein shall be and remain in effect
notwithstanding the discovery or existence of any such additional or different facts, as to which Employee expressly assume the risk. 
  
 [Signature Page Follows] 

 IN WITNESS WHEREOF, the undersigned has executed this General Release of Claims as of the date set forth
below. 
  

			
	Dated:	 	  

	 	 	Stefan AignerChange of Control Agreement / Stefan Aigner

 Exhibit 10.12 
  
 CHANGE OF CONTROL AGREEMENT 
  
 THIS CHANGE OF CONTROL AGREEMENT (“Agreement”) dated as of March 19, 2002 is entered by and between Stefan
Aigner (“Executive”) and Reliant Pharmaceuticals, LLC, a Delaware limited liability company (the “Company”). 
  
 WITNESSETH: 
  
 WHEREAS, Executive is an employee of the Company and has made and is expected to continue to make major contributions to the short and long term
profitability, growth and financial strength of the Company; 
  
 WHEREAS, the Company recognizes that the possibility of a Change of Control (as defined below) exists; and 
  
 WHEREAS, the Company believes it is in the best interests of the Company and its Members to provide an incentive for Executive’s continued employment
and assistance in consummating any such Change of Control. 
  
 NOW
THEREFORE, in exchange for the good and valuable consideration set forth herein, the adequacy of which is specifically acknowledged, the Company and Executive hereby agree as follows: 
  
 1. Certain Defined Terms. Capitalized terms used but not otherwise defined in this Agreement have the meanings
ascribed to them in the LLC Agreement. In addition to terms defined elsewhere in this Agreement, the following capitalized terms shall have the meanings ascribed below when used in this Agreement: 
  
 (a) “Benefits” shall mean medical, dental, and group term
life plans as are established by the Company and as in effect from time to time applicable to executives of the Company or any Successor. 
  
 (b) “Cause” shall mean termination by the Company of the Executive’s relationship with the Company due to (i) the commission by the
Executive of an act of fraud or embezzlement against the Company or any affiliate thereof, (ii) a breach by the Executive of one or more of the following duties to the Company: (A) the duty of loyalty, (B) the duty not to engage in self-dealing with
respect to the Company’s assets, properties or business opportunities, except as approved in writing by the Board, (C) the duty of honesty or (D) any other fiduciary duty which the Executive owes to the Company, (iii) a conviction of the
Executive (or a plea of nolo contendere in lieu thereof) for (A) a felony or (B) a crime involving fraud, dishonesty or moral turpitude, (iv) intentional misconduct with respect to his duties to the Company, including, but not limited to,
knowing and intentional violation by the Executive of written policies of the Company, including policies regarding confidential information and non-competition, or specific directions of the Board or superior officers of the Company, which policies
or directives are neither illegal (or do not involve illegal conduct) nor do they require the Executive to violate reasonable business ethical standards, or (v) the failure of the Executive, after written notice from the Company, to render services
to the Company in accordance with his employment or other relationship with the Company, which failure is not cured within 10 days of receipt of such notice. 

 (c) “Change of Control” shall mean (i) the sale, lease, exchange, license or other
disposition of all or substantially all of Company’s assets in one transaction or series of related transactions (an “Asset Sale”); (ii) a merger or consolidation as a result of which the holders of Company’s issued and
outstanding voting securities immediately before such transaction own or control less than a majority of the voting securities of the continuing or surviving entity immediately after such transaction and/or (iii) the acquisition (in one or more
transactions) by any Person or Persons acting together or constituting a “group” under Section 13(d) of the Exchange Act together with any affiliates thereof (other than Members of the Company as of the date hereof and their respective
affiliates) of beneficial ownership (as defined in Rule 13d-3 under such Exchange Act) or control, directly or indirectly, of at least eighty percent (80%) of the total voting power of all classes of securities entitled to vote generally in the
election of the Company’s board of managers or similar governing body; provided that for the purposes of the immediately preceding clause (iii) neither a public offering of Company’s securities nor any financing transaction or series of
financing transactions shall constitute a Change of Control. 
  
 (d) “Closing Date” shall mean the effective date of a Change of Control. 
  
 (e) “Common Units” shall mean the Class A common units of the Company. 
  
 (f) “Consideration” shall mean the consideration (whether cash, stock or other property) actually received
by (i) the Members of the Company in a Change of Control for or on account of their Units and (ii) employees or former employees of the Company on account of their Options. 
  
 (g) “Employment Agreement” shall mean the Amended and Restated Employment and Non-Competition Agreement
dated as of July 6, 2000 by and between the Company and Executive. 
  
 (h) “Good Reason” shall mean (i) Good Reason within the meaning of the Employment Agreement, (ii) Executive is not offered continued employment with the successor entity in the Change of Control that is comparable in
compensation and generally comparable in position and duties (taking into consideration the Change of Control) to Executive’s compensation, position and duties in effect immediately prior to the Closing Date, (iii) following the Closing Date
and without Executive’s consent, Executive is relocated for at least six (6) months by the Company (or its successor in the Change of Control) to a location more than seventy-five (75) miles from Executive’s current principal place of
employment or (iv) in connection with an Asset Sale, failure by the Successor to assume the Employment Agreement. 
  
 (i) “Liquidation Preference” shall mean the sum of (a) the Series A Liquidation Preference and (b) the Series B Liquidation Preference.

  
 (j) “LLC Agreement” shall mean the Second
Amended and Restated Limited Liability Company Operating Agreement of Reliant Pharmaceuticals, LLC, dated as of February 21, 2002, among the Members named therein, as amended from time to time. 
  

 2 

 (k) “Option” shall mean outstanding options to purchase Common Units granted pursuant to
the Plan. 
  
 (l) “Plan” shall mean the Reliant
Pharmaceuticals LLC Equity Incentive Plan dated as of July 6, 2001, as amended. 
  
 (m) “Restricted Units” shall mean Common Units acquired upon exercise of any unvested Option or otherwise granted to the Executive under the terms of or subject to the Plan. 
  
 (n) “Successor” means a successor in interest to the Company
or the Company’s assets in a Change of Control. 
  
 (o)
“Value” means the total value of Consideration actually received by the Series A Holders and Series B Holders, as the case may be, in a Change of Control that would be applied in satisfaction of such holders’ Liquidation
Preference. 
  
 2. Term of Agreement. This Agreement shall
be effective on the Closing Date for a period of nine (9) consecutive months immediately following the Closing Date; provided, that any rights of Executive and/or the Company which are triggered and accrue hereunder during the term of this Agreement
shall survive the termination of this Agreement to the extent so accrued. 
  
 3. Amendment of Employment Agreement. During the term of this Agreement, any provisions of the Employment Agreement that are inconsistent with the terms of this Agreement shall be amended to conform to the
terms of this Agreement. Without limiting the foregoing, it is specifically understood and agreed that (a) during the term of this Agreement the definitions of Cause and Good Reason contained herein shall supercede and replace those contained in the
Employment Agreement and (b) subject to the terms hereof, the Employment Agreement will remain in full force and effect in accordance with its terms. 
  
 4. Severance. If during the term of this Agreement, Executive’s employment is terminated without Cause or for Good Reason, then such
termination shall be treated as a termination without Cause or for Good Reason pursuant to the terms of the Employment Agreement and the Executive shall be entitled to rights provided thereunder in respect of such termination. In the event of an
Asset Sale, the Company’s obligations under the Employment Agreement to continue providing the Benefits following a termination without Cause or for Good Reason shall cease, unless otherwise required by law, and/or any Successor agrees to
continue providing such Benefits. In addition, if Executive becomes entitled to receive Benefits under any subsequent employer’s benefit and/or welfare plans, the Company’s obligations to continue the Benefits as a result of termination
without Cause or for Good Reason under the Employment Agreement shall cease. 
  
 5. Bonus. 
  
 (a) Subject
to Section 5(c) below, in the event that (i) a Change of Control occurs prior to (A) the date the Company first offers its equity securities to the public pursuant to an effective registration statement under the Securities Act of 1933, as amended,
or (B) the date on which the Series A Holders and Series B Holders convert 50% or more of their Series A 
  

 3 

 Preferred Units and Series B Preferred Units, respectively, to Common Units in accordance with Section 6.2 of the LLC
Agreement, (ii) the Executive is terminated without Cause or terminates his employment under the circumstances described in clauses (ii) or (iii) of the definition of Good Reason, and (iii) upon the Change of Control the Series A Holders and Series
B Holders receive aggregate Value equal to at least the Liquidation Preference, but not more than the Series A/B Liquidation Preference Cap, then Executive shall have the right to receive a bonus equal to one times (1x) his annual base salary in
effect immediately prior to the Change of Control (the “Bonus”); provided, that Executive is employed by the Company on the Closing Date (or has been terminated without Cause or has terminated his employment by the Company with Good
Reason (as defined in the Employment Agreement), in each case within the three month period immediately prior to the Closing Date). In the event that the Series A Holders and the Series B Holders receive Value in the Change of Control (1) of less
than the Liquidation Preference or (2) in excess of the Series A/B Liquidation Preference Cap, in each case after giving effect to any bonus payments made or to be made by Reliant pursuant to the terms of this Agreement and other similar change of
control agreements or severance agreements entered into between the Company and the persons listed on Annex A attached hereto, then, in either case, Executive shall not be entitled to any Bonus. 
  
 The Bonus, if any, shall be (x) payable upon the later of (1) ten business
days following the termination of Executive’s employment with the Company and (2) ten business days following the Closing Date, (y) paid in a cash lump sum and (z) shall be in addition to and not in substitution of any severance to which
Executive is otherwise entitled under the terms of the Employment Agreement. 
  
 (b) Upon becoming entitled to receive the Bonus and in consideration of the Company’s agreement to pay such Bonus to Executive in accordance with Section 5(a) above, immediately prior to the consummation of the
Change of Control, (i) if the Executive holds any Options, Executive shall forfeit all right to any Options held by Executive and such Options shall be deemed cancelled effective immediately prior to the Change of Control and (ii) if Executive holds
Common Units, such Common Units will be redeemed for an aggregate redemption price of $1.00 by the Company and Executive shall have no further rights to such Common Units with such Common Units being deemed cancelled immediately prior to the Change
of Control. 
  
 (c) In the event the Value of the Change of
Control is reduced as a result of the payment made by any claims of the acquiring Person based upon (i) breaches in representations or warranties made by or on behalf of Reliant, or (ii) rights of indemnification against Reliant or its Members in
connection with the Change of Control, as the case may be, (collectively, “Losses”), such that the Value (as adjusted for such Losses) received by the Series A Holders and the Series B Holders is less than the Liquidation
Preference, then Executive agrees to pay to the Series A Holders and the Series B Holders on a pro rata basis the full amount of the Bonus. Bay City Capital Fund II, L.P. (“BCC Fund II”) on behalf of the Series A Holders and the
Series B Holders shall re-calculate the Value after giving effect to any Losses, and in the event that the amount of such Losses reduce the Value to an amount below the Liquidation Preference, BCC Fund II shall inform Executive in writing of the
total amount of such Losses and the re-calculation of Value (the “Notice”). Within 10 business days of delivery of the Notice, Executive will remit to BCC Fund II on behalf of the Series A Holders and the Series B Holders cash in
the amount of 50% of the Bonus and an unsecured recourse promissory 
  

 4 

 note in the original principal amount equal to 50% of the Bonus made in favor of BCC Fund II (not individually, but
rather as disbursement agent for the Series A Holders and the Series B Holders) in form and substance reasonably satisfactory to BCC Fund II (the “Bonus Repayment Note”), which Bonus Repayment Note will provide, among others terms,
for (i) interest at the rate of the prime rate as announced by Bank of America, NA payable quarterly in arrears, (ii) repayment of 50% of the original principal amount of the Bonus Repayment Note, plus any accrued but unpaid interest thereon
90 days following the date of the Note, (iii) repayment of the balance of the Bonus Repayment Note, including any accrued but unpaid interest thereon on the first anniversary of the Bonus Repayment Note and (iv) prepayment of the Bonus Repayment
Note without penalty or premium upon three business days prior written notice to BCC Fund II. The Series A Holders and the Series B Holders shall be third-party beneficiaries to the provisions of this Section 5(c). 
  
 6. Vesting and Option Exercise Period. 
  
 (a) Notwithstanding anything to the contrary contained in the Plan or the
applicable Option or Restricted Unit agreements between the Company and Executive, upon consummation of Change of Control, Executive shall be fully vested in all of his Options and Restricted Units as of the Closing Date. In addition to the
foregoing, in the event that the Executive’s Options or Restricted Units are exchanged in the Change of Control for securities of a publicly traded entity, then upon such exchange, such securities will be free from all call rights, repurchase
rights and transfer restrictions imposed by the Plan, any applicable Option agreement and/or any applicable Restricted Unit agreement to the extent that such call rights, repurchase rights and transfer restrictions would have terminated in
accordance with the terms of such Plan, Option agreement and/or Restricted Unit agreement following the initial public offering of the Company’s securities. 
  
 (b) Notwithstanding anything to the contrary contained in the Plan or any applicable Option agreement between the Company
and the Executive, if the Executive’s employment is terminated within the 12-month period following a Change of Control and during any period in which the Executive is prohibited from exercising the Option or selling any units or shares
acquired upon exercise of the Option by reason of the any Federal or state securities laws or the terms of a lock-up agreement or similar agreement, then the period in which the Executive may exercise such Option following his termination of
employment shall be extended until 30 days after the date the Executive is not so restricted from exercising such Option and/or selling any units or shares acquired upon exercise of such Option. 
  
 7. 280G Provisions. 
  
 (a) This Agreement shall not be effective and shall be of no force and
effect unless and until this Agreement has been approved by the persons holding more that 75% of the voting power of the Company in accordance with Section 280G(b)(5)(B) of the Internal Revenue Code of 1986, as amended (the “Code”);
provided, however, that (i) in the event the Company determines that the provisions of Section 280G of the Code do not apply to the Company due to its status as a limited liability company, or (ii) shares of the Company are readily tradable on an
established securities market immediately prior to such Change of Control then no such approval shall be required. 
  

 5 

 (b) Anything in this Agreement to the contrary notwithstanding, the aggregate payments or distributions
by the Company or any of its affiliates to or for the benefit of Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise pursuant to or by reason of any other agreement, policy, plan,
program or arrangement, including without limitation any Option, Restricted Units, the Plan or similar right, or the lapse or termination of any restriction on or the vesting or exercisability of any of the foregoing (collectively, a
“Payment”), shall not exceed the maximum Payments which Executive can receive without being subject to the excise tax imposed by Section 4999 of the Code (or any successor provision thereto) by reason of being considered
“contingent on a change in ownership or control” of the Company, within the meaning of Section 280G of the Code (or any successor provision thereto) or to any similar tax imposed by state or local law, or any interest or penalties with
respect to such tax (such tax or taxes, together with any such interest and penalties, being hereafter collectively referred to as the “Excise Tax”), and the Payments shall be reduced to the extent necessary so that the Executive
shall not incur any Excise Tax. 
  
 (c) The determination of
whether or not the Payments shall subject the Executive to the Excise Tax and/or the amount of reduction of any such Payments in order to comply with the requirements of Section 8(b) shall be made by the certified public accounting firm which serves
as the Company’s outside auditors immediately prior to the Change of Control (the “Accounting Firm”). The Company and Executive shall each provide the Accounting Firm access to and copies of any books, records and documents in
the possession of the Company or Executive, as the case may be, reasonably requested by the Accounting Firm, and otherwise cooperate with the Accounting Firm in connection with the preparation and issuance of the determination and calculations
contemplated by Section 8(b). Any final determination by the Accounting Firm shall be final and binding upon the Company and Executive. 
  
 (d) To the extent possible, the Payments shall be reduced first from any cash payments such as Bonus, and severance payable to Executive. If after
reduction of all cash Payments, the Payments would still cause Executive to incur the Excise Tax, then to the extent necessary Executive’s vesting in such portion of the Options and or Restricted Units which would result in the Excise Tax not
being triggered shall not be accelerated. 
  
 8.
Confidentiality. Executive agrees not to discuss or disclose the terms or existence of this Agreement, any contemplated Change of Control or the status of any discussion or negotiation related to a possible Change of Control with or to any
person, agency, institution, company, or other entity (including, without limitation, a potential buyer of any asset of the Company and any of such buyer’s directors, officers, representatives, agents, counsel or accountants) unless the
officers of Company responsible for negotiating the Change of Control agree in writing to such disclosure in advance, provided that Executive may, without such permission, make such disclosures as are required by courts or government agencies
of appropriate jurisdiction or otherwise by law, and disclose the terms of this Agreement to his attorney(s), accountant(s), tax advisor(s), and other professional service provider(s), as reasonably necessary, and to his spouse and immediate family.
However, to the extent Executive permissibly discloses information about the terms of his Agreement, Executive agrees to instruct such person(s) that the terms of this Agreement are strictly confidential and are not to be revealed to anyone else
except as required by law. 
  

 6 

 9. Cooperation. Executive hereby agrees to cooperate with the Company and its Members in their
efforts to negotiate and consummate any Change of Control. Without limiting the foregoing, Executive agrees that (a) he shall make himself available at the Company’s reasonable request from time to time at such times and in such places as
Executive and the Company may reasonably determine to answer questions and provide information to potential parties to a Change of Control in a manner consistent with the policies, procedures and guidelines established by the Company and its
advisors and disclosed to Executive and (b) to the extent requested to do so by the Finance Committee of the Board of Mangers, he shall otherwise support any Change of Control and assist in connection with the negotiation and consummation of any
Change of Control. 
  
 10. Injunctive Relief. Executive
agrees that his failure to comply with Sections 9 and 10 of this Agreement will cause irreparable harm to the Company, and that money damages would not adequately compensate the Company for such harm. Executive hereby agrees that in addition to any
other remedy that may be available at law or equity hereunder or otherwise, the Company shall be entitled to injunctive or other equitable relief to restrain any breach or attempted breach by him of such terms and the Company shall be entitled to
apply for such relief to any court of competent jurisdiction without the posting of any bond or other security. 
  
 11. Successors and Binding Agreement. 
  
 (a) This Agreement will be binding upon and inure to the benefit of the Company and any successor to the Company, including, any Successor (and such
successor shall thereafter be deemed the “Company” for the purpose of this Agreement), but will not otherwise be assignable, transferable or delegable by the Company. 
  
 (b) This Agreement will inure to the benefit of and be enforceable by the Executive’s personal or legal
representatives, executors, administrators, successors, heirs, distributees and legatees. 
  
 (c) This Agreement is personal in nature and neither of the parties hereto shall, without the consent of the other, assign, transfer or delegate this Agreement or any rights or obligations hereunder, except as
expressly provided in Section 12(a) and (b). Without limiting the generality or effect of the foregoing, the Executive’s right to receive payments hereunder will not be assignable, transferable or delegable, whether by pledge, creation of a
security interest, or otherwise, other than by a transfer by Executive’s will or by the laws of descent and distribution and, in the event of any attempted assignment or transfer contrary to this Section 12(c), the Company shall have no
liability to pay any amount so attempted to be assigned, transferred or delegated. 
  
 12. Miscellaneous. 
  
 (a)
Taxes. All amounts payable hereunder shall be subject to applicable federal, state and local tax withholding. 
  
 (b) Severability. If any provision of this Agreement is held by a court of competent jurisdiction to be invalid, illegal or unenforceable, such
provision shall be severed and enforced to the extent possible or modified in such a way as to make it enforceable, and the invalidity, illegality or unenforceability thereof shall not affect the validity, legality or enforceability of the remaining
provisions of this Agreement. 
  

 7 

 (c) Governing Law; Jurisdiction. This Agreement shall be governed by and construed in accordance
with the laws of the State of Delaware applicable to contracts executed in and to be performed entirely within that state, except with respect to matters of law concerning the internal corporate affairs of any corporate entity which is a party to or
the subject of this Agreement, and as to those matters, the law of the jurisdiction under which the respective entity derives its powers shall govern. The parties irrevocably agree that all actions to enforce an arbitrator’s decision pursuant
to Section 13(f) of this Agreement may be instituted and litigated in federal, state or local courts sitting in the Borough of Manhattan, City of New York, New York and each of such parties hereby consents to the non-exclusive jurisdiction and venue
of such court and waives any objection based on forum non conveniens. 
  
 (d) WAIVER OF JURY TRIAL. THE PARTIES HEREBY WAIVE, RELEASE AND RELINQUISH ANY AND ALL RIGHTS THEY MAY HAVE TO A TRIAL BY JURY WITH RESPECT TO ANY ACTIONS TO ENFORCE AN ARBITRATOR’S DECISION PURSUANT TO
SECTION 13(f) OF THIS AGREEMENT. 
  
 (e) Notices. Any
notices required or permitted to be sent hereunder shall be delivered personally, via facsimile transmission (with confirmation), or mailed, via certified mail (return receipt requested), or delivered by overnight courier service to the following
addresses, or such other address as any party hereto designates by written notice to the Company, and shall be deemed to have been given upon delivery, if delivered personally or via facsimile, three (3) business days after mailing, if mailed, or
one (1) business day after delivery to the courier, if delivered by overnight courier service: 
  
 if to the Company to: 
  
 Reliant Pharmaceuticals, LLC 
 110 Allen Road 
 Liberty Corner, New Jersey 07938 
 Attention: President 
 Telecopy: (908) 542-9406 
  
 with copies sent concurrently to: 
  
 Reliant Pharmaceuticals, LLC 
 110 Allen Road 
 Liberty Corner, New Jersey 07938 
 Attention: General Counsel 
 Telecopy: (908) 542-9406 
  
 Latham & Watkins 
 Sears Tower, Suite 5800 
 233 South Wacker Drive 
 Chicago, Illinois 60606 
 Attention: Michael A. Pucker 
 Telecopy: (312) 993-9767 
  

 8 

 If to Executive, to him at his most recent address as reflected in the Company’s records. Either
party may change its address for notice under this Section 13(e) upon written notice to the other party, such notice to be effective upon receipt. 
  
 (f) Arbitration. Except as provided in Section 13(c) hereof, in the event that there shall be a dispute among the parties arising out of or
relating to this Agreement, or the breach thereof, the parties agree that such dispute shall be resolved by final and binding arbitration in the Borough of Manhattan, City of New York, New York, administered by the American Arbitration Association
(the “AAA”), in accordance with AAA’s Commercial Arbitration Rules, to which shall be added the provisions of the Federal Rules of Civil Procedure relating to the Production of Evidence, and the parties agree that the
arbitrators may impose sanctions in their discretion to enforce compliance with discovery and other obligations. Such arbitration shall be presided over by a single arbitrator. If Executive, on the one hand, and the Company, on the other hand, do
not agree on the arbitrator within fifteen (15) days after a party requests arbitration, the arbitrator shall be selected by the Company and Executive from a list of five (5) potential arbitrators provided by AAA. Such list shall be provided within
ten (10) days of the request of any party for arbitration. The party requesting arbitration shall delete one name from the list. The other party shall delete one name from the list. This process shall then be repeated in the same order, and the last
remaining person on the list shall be the arbitrator. This selection process shall take place within the two (2) business days following both parties’ receipt of the list of five (5) potential arbitrators. Hearings in the arbitration
proceedings shall commence within twenty (20) days of the selection of the arbitrator or as soon thereafter as the arbitrator is available. The arbitrator shall deliver his or her opinion within twenty (20) days after the completion of the
arbitration hearings. The arbitrator’s decision shall be final and binding upon the parties, and may be entered and enforced in any court of competent jurisdiction by either of the parties. The arbitrator shall have the power to grant
temporary, preliminary and permanent relief, including without limitation, injunctive relief and specific performance. Unless otherwise ordered by the arbitrator pursuant to this Agreement, the arbitrator’s fees and expenses shall be shared
equally by the parties. 
  
 (g) Attorneys’ Fees. If
any arbitration is brought under Section 13(f), the arbitrator may award the successful or prevailing party reasonable attorneys’ fees and other costs incurred in that action or proceeding, in addition to any other relief to which it may be
entitled. If any other proceeding is brought by one party against the other in connection with or relating in any manner to this Agreement, or to enforce an arbitration award, the successful or prevailing party (as determined by an independent
third-party, e.g. a judge) shall be entitled to recover its reasonable attorneys’ fees and other costs incurred in that action or proceeding, in addition to any other relief to which it may be entitled. 
  
 (h) Entire Agreement. This Agreement constitutes the entire
understanding among all of the parties hereto and supersedes any prior understandings and agreements, written or oral, among them respecting the subject matter hereof. 
  
 (i) Amendment. This Agreement may be amended only by a written instrument signed by each of the parties hereto.

  

 9 

 (j) Not Compensation. Amounts payable pursuant to this Agreement shall not constitute
“compensation” for purposes of any pension, welfare or other benefit plan or policy of the Company unless expressly provided for therein. 
  
 (k) Counterparts. This Agreement may be executed simultaneously in two or more counterparts, each of which shall be deemed an original, but all of
which together shall constitute one and the same instrument. 
  
 (l) Members Discretion to Consummate a Change of Control. Executive agrees and acknowledges that neither the Company nor the Members are under any obligation to in respect of consummating any Change of Control. 
  
 (m) Opportunity to Review. The Company and Executive have carefully
read this Agreement in its entirety; fully understand and agree to its terms and provisions; and intend and agree that it is final and binding on all parties. 
  

(n) No Presumption Against Drafter. Each of the parties hereto has jointly participated in the negotiation and drafting of this Agreement. In
the event there arises any ambiguity or question of intent or interpretation with respect to this Agreement, this Agreement shall be construed as if drafted jointly by the parties hereto and no presumptions or burdens of proof shall arise favoring
any party by virtue of the authorship of any of the provisions of this Agreement. 
  
 [Signature page to Change of Control Agreement Follows Immediately] 
  

 10 

 [Signature Page to Change of Control Agreement] 
  
 IN WITNESS WHEREOF, and intending to be legally bound, the Company and
Executive have executed the foregoing as of the date first written above. 
  

			
	EXECUTIVE
	
	 /s/ Stefan Aigner

	Stefan Aigner
	
	RELIANT PHARMACEUTICALS, LLC
		
	By:	 	 /s/ Joseph J. Krivulka

	Name:	 	Joseph J. Krivulka
	Title:	 	President

  
 Agreed to and Accepted Solely

 as to Section 5(c) hereof: 
  
 BAY CITY CAPITAL FUND II, L.P. 
  

			
	By:	 	Bay City Capital Management II, L.P.
		
	By:	 	 /s/ Fred Craves

	Name:	 	 
	Title:	 	 

  

 11 

 ANNEX A 
 to 
 Change of Control Agreement 
  
 Vincent Angotti 
 George Bobotas 
 A. Steven Franchak 
 Gregory Fulton 
 Lawrence Gyenes 
 Joseph Krivulka 
 Michael Lerner 
 Neil Manowitz 
 Keith Rotenberg 
 Gary Talarico

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00085-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00085-of-00352.parquet"}]]